MSLN and gastric cancer: Other targets that entered clinical trials of gastric cancer primarily included HER2 (NCT04660929), CEA (NCT05396300), MUC1 (NCT05239143), EpCAM (NCT05028933, NCT03563326), MSLN (NCT03941626), EGFR (NCT03740256), B7H3 (NCT04864821) and NKG2DL (NCT04550663), with no conclusions reported yet.